Literature DB >> 26575243

Proteomic and Lipidomic Analysis of Nanoparticle Corona upon Contact with Lung Surfactant Reveals Differences in Protein, but Not Lipid Composition.

Simon Sebastian Raesch1,2, Stefan Tenzer3, Wiebke Storck3, Alexander Rurainski4, Dominik Selzer4, Christian Arnold Ruge1, Jesus Perez-Gil5, Ulrich Friedrich Schaefer1, Claus-Michael Lehr1,2.   

Abstract

Pulmonary surfactant (PS) constitutes the first line of host defense in the deep lung. Because of its high content of phospholipids and surfactant specific proteins, the interaction of inhaled nanoparticles (NPs) with the pulmonary surfactant layer is likely to form a corona that is different to the one formed in plasma. Here we present a detailed lipidomic and proteomic analysis of NP corona formation using native porcine surfactant as a model. We analyzed the adsorbed biomolecules in the corona of three NP with different surface properties (PEG-, PLGA-, and Lipid-NP) after incubation with native porcine surfactant. Using label-free shotgun analysis for protein and LC-MS for lipid analysis, we quantitatively determined the corona composition. Our results show a conserved lipid composition in the coronas of all investigated NPs regardless of their surface properties, with only hydrophilic PEG-NPs adsorbing fewer lipids in total. In contrast, the analyzed NP displayed a marked difference in the protein corona, consisting of up to 417 different proteins. Among the proteins showing significant differences between the NP coronas, there was a striking prevalence of molecules with a notoriously high lipid and surface binding, such as, e.g., SP-A, SP-D, DMBT1. Our data indicate that the selective adsorption of proteins mediates the relatively similar lipid pattern in the coronas of different NPs. On the basis of our lipidomic and proteomic analysis, we provide a detailed set of quantitative data on the composition of the surfactant corona formed upon NP inhalation, which is unique and markedly different to the plasma corona.

Entities:  

Keywords:  biological barrier; bionano interface; bronchoalveolar lining fluid; inhalation; lipid−protein interaction; magnetic separation; nanoparticle surface

Mesh:

Substances:

Year:  2015        PMID: 26575243     DOI: 10.1021/acsnano.5b04215

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  36 in total

Review 1.  Using Large Datasets to Understand Nanotechnology.

Authors:  Kalina Paunovska; David Loughrey; Cory D Sago; Robert Langer; James E Dahlman
Journal:  Adv Mater       Date:  2019-08-20       Impact factor: 30.849

2.  Formation of a protein corona influences the biological identity of nanomaterials.

Authors:  Daniel Nierenberg; Annette R Khaled; Orielyz Flores
Journal:  Rep Pract Oncol Radiother       Date:  2018-05-28

Review 3.  Toward a systematic exploration of nano-bio interactions.

Authors:  Xue Bai; Fang Liu; Yin Liu; Cong Li; Shenqing Wang; Hongyu Zhou; Wenyi Wang; Hao Zhu; David A Winkler; Bing Yan
Journal:  Toxicol Appl Pharmacol       Date:  2017-03-24       Impact factor: 4.219

4.  The role of natural processes and surface energy of inhaled engineered nanoparticles on aggregation and corona formation.

Authors:  Akira Tsuda; Nagarjun Konduru Venkata
Journal:  NanoImpact       Date:  2016-06-11

5.  Effect of pulmonary surfactant on the dissolution, stability and uptake of zinc oxide nanowires by human respiratory epithelial cells.

Authors:  Ioannis G Theodorou; Pakatip Ruenraroengsak; Andrew Gow; Stephan Schwander; Junfeng Jim Zhang; Kian Fan Chung; Teresa D Tetley; Mary P Ryan; Alexandra E Porter
Journal:  Nanotoxicology       Date:  2016-08-11       Impact factor: 5.913

6.  Disease Models: Lung Models for Testing Drugs Against Inflammation and Infection.

Authors:  Patrick Carius; Justus C Horstmann; Cristiane de Souza Carvalho-Wodarz; Claus-Michael Lehr
Journal:  Handb Exp Pharmacol       Date:  2021

Review 7.  Emerging concepts and directed therapeutics for the management of asthma: regulating the regulators.

Authors:  Madhur D Shastri; Wai Chin Chong; Kamal Dua; Gregory M Peterson; Rahul P Patel; Malik Q Mahmood; Murtaza Tambuwala; Dinesh K Chellappan; Nicole G Hansbro; Shakti D Shukla; Philip M Hansbro
Journal:  Inflammopharmacology       Date:  2020-11-05       Impact factor: 4.473

Review 8.  Technological strategies to estimate and control diffusive passage times through the mucus barrier in mucosal drug delivery.

Authors:  Jay M Newby; Ian Seim; Martin Lysy; Yun Ling; Justin Huckaby; Samuel K Lai; M Gregory Forest
Journal:  Adv Drug Deliv Rev       Date:  2017-12-12       Impact factor: 15.470

Review 9.  Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases.

Authors:  Caleb F Anderson; Maria E Grimmett; Christopher J Domalewski; Honggang Cui
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-10-10

Review 10.  Biocompatibility of nanomaterials and their immunological properties.

Authors:  Themis R Kyriakides; Arindam Raj; Tiffany H Tseng; Hugh Xiao; Ryan Nguyen; Farrah S Mohammed; Saiti Halder; Mengqing Xu; Michelle J Wu; Shuozhen Bao; Wendy C Sheu
Journal:  Biomed Mater       Date:  2021-03-11       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.